F-Star Therapeutics Inc (FSTX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Eliot R. Forster
Employees:
90
35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT
44 1223 497400

F-star Therapeutics, Inc. develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118.

Data derived from most recent annual or quarterly report
Market Cap 156.511 Million Shares Outstanding21.982 Million Avg 30-day Volume 825.279 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.84
Price to Revenue5.2847 Debt to Equity0.213 EBITDA-34.966 Million
Price to Book Value1.9654 Operating Margin-173.5632 Enterprise Value88.462 Million
Current Ratio3.381 EPS Growth-3.306 Quick Ratio2.424
1 Yr BETA 0.8191 52-week High/Low 7.12 / 2.07 Profit Margin-211.32
Operating Cash Flow Growth24.4078 Altman Z-Score-0.2866 Free Cash Flow to Firm -30.011 Million
View SEC Filings from FSTX instead.

View recent insider trading info

F-Star Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding FSTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FSTX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-09 by KAYITALIRE LOUIS
  • 4: filed on 2023-03-09 by FORSTER ELIOT
  • 4: filed on 2023-03-09 by KLEIN PAMELA M.
  • 4: filed on 2023-03-09 by DEPTULA-HICKS DARLENE M
  • 4: filed on 2023-03-09 by BRADY TODD C
  • 4: filed on 2023-03-09 by BREWIS NEIL
  • 4: filed on 2023-03-09 by RACE GEOFFREY
  • 4: filed on 2023-03-09 by BERMINGHAM NESSAN
  • 4: filed on 2023-03-09 by BENZ EDWARD JR
  • 4: filed on 2023-03-09 by ARKOWITZ DAVID

    • Events (8k)

  • 8-K: filed on 2023-03-09:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-07:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-06:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-23:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
  • 8-K: filed on 2023-02-09:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-01:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-30:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-29:
    Item 8.01: Other Events
  • 8-K: filed on 2022-12-21:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-19:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    DEPTULA-HICKS DARLENE M SEE REMARKS

    • Officer
    		 0 2023-03-08 2

    BERMINGHAM NESSAN

    • Director
    		 0 2023-03-08 2

    BREWIS NEIL CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2023-03-08 3

    KAYITALIRE LOUIS CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-03-08 2

    FORSTER ELIOT PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2023-03-08 3

    BENZ EDWARD JR

    • Director
    		 0 2023-03-08 2

    RACE GEOFFREY

    • Director
    		 0 2023-03-08 3

    ARKOWITZ DAVID

    • Director
    		 20,000 2022-06-17 1

    BRADY TODD C

    • Director
    		 20,000 2022-06-17 1

    KLEIN PAMELA M.

    • Director
    		 20,000 2022-06-17 1

    KROL PATRICK JOHAN HENDRIK

    • Director
    		 20,000 2021-06-04 0

    DRISCOLL MARTIN J PRESIDENT AND CEO

    • Officer
    • Director
    		 No longer subject to file 2020-11-19 0

    EICHLER KURT M

    • Director
    		 No longer subject to file 2020-11-19 0

    IYER RADHAKRISHNAN P. CHIEF SCIENTIFIC OFFICER

    • Officer
    		 No longer subject to file 2020-11-19 0

    WINSLOW GARRETT GENERAL COUNSEL AND SECRETARY

    • Officer
    		 No longer subject to file 2020-11-19 0

    FIRMANI LORI VP OF FINANCE AND TREASURER

    • Officer
    		 No longer subject to file 2020-11-19 0

    CLACKSON TIMOTHY P

    • Director
    		 50,486 2020-09-30 0

    SMITH SCOTT ANDREW

    • Director
    		 0 2020-06-24 0

    FREVE JONATHAN CFO & TREASURER

    • Officer
    		 0 2020-03-05 0

    AFDHAL NEZAM H. CHIEF MEDICAL OFFICER

    • Officer
    		 0 2019-01-24 0

    BARDON CHRISTIANA

    • Director
    • 10% Owner
    		 890,959 2018-10-01 0

    BATES JONATHAN

    • Director
    		 0 2018-06-18 0

    MPM ONCOLOGY IMPACT MANAGEMENT GP LLC

    MPM ONCOLOGY IMPACT MANAGEMENT LP

    ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.

    UBS ONCOLOGY IMPACT FUND L.P.

    • 10% Owner
    		 833,839 2017-03-25 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    KAYITALIRE LOUIS - Officer CHIEF MEDICAL OFFICER

    		2023-03-09 09:21:33 -0500 2023-03-08 D 25,019 $7.12 d 0 direct

    BREWIS NEIL - Officer CHIEF SCIENTIFIC OFFICER

    		2023-03-09 09:16:39 -0500 2023-03-08 D 132,469 d 0 direct

    KLEIN PAMELA M. - Director

    		2023-03-09 09:18:56 -0500 2023-03-08 D 20,000 d 0 direct

    KLEIN PAMELA M. - Director

    		2023-03-09 09:18:56 -0500 2023-03-08 D 20,000 d 0 direct

    DEPTULA-HICKS DARLENE M - Officer SEE REMARKS

    		2023-03-09 09:18:39 -0500 2023-03-08 D 24,902 d 0 direct

    DEPTULA-HICKS DARLENE M - Officer SEE REMARKS

    		2023-03-09 09:18:39 -0500 2023-03-08 D 25,539 $7.12 d 0 direct

    DEPTULA-HICKS DARLENE M - Officer SEE REMARKS

    		2023-03-09 09:18:39 -0500 2023-03-08 D 25,894 d 0 direct

    DEPTULA-HICKS DARLENE M - Officer SEE REMARKS

    		2023-03-09 09:18:39 -0500 2023-03-08 D 28,426 d 0 direct

    DEPTULA-HICKS DARLENE M - Officer SEE REMARKS

    		2023-03-09 09:18:39 -0500 2023-03-08 U 30,898 $7.12 d 25,539 direct

    DEPTULA-HICKS DARLENE M - Officer SEE REMARKS

    		2023-03-09 09:18:39 -0500 2023-03-08 D 59,823 d 0 direct

    KAYITALIRE LOUIS - Officer CHIEF MEDICAL OFFICER

    		2023-03-09 09:21:33 -0500 2023-03-08 D 12,880 d 0 direct

    BREWIS NEIL - Officer CHIEF SCIENTIFIC OFFICER

    		2023-03-09 09:16:39 -0500 2023-03-08 U 105,088 $7.12 d 9,375 direct

    KAYITALIRE LOUIS - Officer CHIEF MEDICAL OFFICER

    		2023-03-09 09:21:33 -0500 2023-03-08 D 27,289 d 0 direct

    KAYITALIRE LOUIS - Officer CHIEF MEDICAL OFFICER

    		2023-03-09 09:21:33 -0500 2023-03-08 U 29,236 $7.12 d 25,019 direct

    KAYITALIRE LOUIS - Officer CHIEF MEDICAL OFFICER

    		2023-03-09 09:21:33 -0500 2023-03-08 D 35,719 d 0 direct

    KAYITALIRE LOUIS - Officer CHIEF MEDICAL OFFICER

    		2023-03-09 09:21:33 -0500 2023-03-08 D 53,634 d 0 direct

    FORSTER ELIOT - Director - Officer PRESIDENT AND CEO

    		2023-03-09 09:20:14 -0500 2023-03-08 D 73,959 $7.12 d 0 direct

    FORSTER ELIOT - Director - Officer PRESIDENT AND CEO

    		2023-03-09 09:20:14 -0500 2023-03-08 D 126,909 d 0 direct

    FORSTER ELIOT - Director - Officer PRESIDENT AND CEO

    		2023-03-09 09:20:14 -0500 2023-03-08 D 127,924 d 0 direct

    FORSTER ELIOT - Director - Officer PRESIDENT AND CEO

    		2023-03-09 09:20:14 -0500 2023-03-08 D 165,028 d 0 direct

    FORSTER ELIOT - Director - Officer PRESIDENT AND CEO

    		2023-03-09 09:20:14 -0500 2023-03-08 U 347,578 $7.12 d 73,959 direct

    BENZ EDWARD JR - Director

    		2023-03-09 09:12:30 -0500 2023-03-08 D 20,000 d 0 direct

    ARKOWITZ DAVID - Director

    		2023-03-09 09:10:45 -0500 2023-03-08 D 20,000 d 0 direct

    ARKOWITZ DAVID - Director

    		2023-03-09 09:10:45 -0500 2023-03-08 D 20,000 d 0 direct

    BERMINGHAM NESSAN - Director

    		2023-03-09 09:12:38 -0500 2023-03-08 D 6,328 $7.12 d 0 direct

    BERMINGHAM NESSAN - Director

    		2023-03-09 09:12:38 -0500 2023-03-08 D 20,000 d 0 direct

    BERMINGHAM NESSAN - Director

    		2023-03-09 09:12:38 -0500 2023-03-08 D 20,000 d 0 direct

    BERMINGHAM NESSAN - Director

    		2023-03-09 09:12:38 -0500 2023-03-08 D 34,111 d 0 direct

    BERMINGHAM NESSAN - Director

    		2023-03-09 09:12:38 -0500 2023-03-08 U 97,547 $7.12 d 6,328 direct

    BENZ EDWARD JR - Director

    		2023-03-09 09:12:30 -0500 2023-03-08 D 3,937 d 0 direct

    BENZ EDWARD JR - Director

    		2023-03-09 09:12:30 -0500 2023-03-08 D 4,385 $7.12 d 0 direct

    BENZ EDWARD JR - Director

    		2023-03-09 09:12:30 -0500 2023-03-08 D 20,000 d 0 direct

    ARKOWITZ DAVID - Director

    		2023-03-09 09:10:45 -0500 2023-03-08 U 8,386 $7.12 d 0 direct

    RACE GEOFFREY - Director

    		2023-03-09 09:14:51 -0500 2023-03-08 U 3,937 $7.12 d 0 direct

    RACE GEOFFREY - Director

    		2023-03-09 09:14:51 -0500 2023-03-08 D 20,000 d 0 direct

    RACE GEOFFREY - Director

    		2023-03-09 09:14:51 -0500 2023-03-08 D 20,000 d 0 direct

    BRADY TODD C - Director

    		2023-03-09 09:17:08 -0500 2023-03-08 U 15,004 $7.12 d 0 direct

    BRADY TODD C - Director

    		2023-03-09 09:17:08 -0500 2023-03-08 D 20,000 d 0 direct

    BRADY TODD C - Director

    		2023-03-09 09:17:08 -0500 2023-03-08 D 20,000 d 0 direct

    BREWIS NEIL - Officer CHIEF SCIENTIFIC OFFICER

    		2023-03-09 09:16:39 -0500 2023-03-08 D 9,375 $7.12 d 0 direct

    BREWIS NEIL - Officer CHIEF SCIENTIFIC OFFICER

    		2023-03-09 09:16:39 -0500 2023-03-08 D 22,561 d 0 direct

    BREWIS NEIL - Officer CHIEF SCIENTIFIC OFFICER

    		2023-03-09 09:16:39 -0500 2023-03-08 D 74,263 d 0 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 22:15:03 UTC -1.1324 5.7024 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 21:45:04 UTC -1.1324 5.7024 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 21:15:04 UTC -1.1324 5.7024 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 20:45:04 UTC -1.7186 6.2886 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 20:15:03 UTC -1.7186 6.2886 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 19:45:04 UTC -1.7186 6.2886 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 19:15:03 UTC -1.7186 6.2886 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 18:45:03 UTC -1.7186 6.2886 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 18:15:04 UTC -1.7186 6.2886 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 17:45:04 UTC -1.7186 6.2886 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 17:15:03 UTC -1.7186 6.2886 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 16:45:03 UTC -1.7186 6.2886 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 16:15:04 UTC -1.7186 6.2886 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 15:45:04 UTC -1.7186 6.2886 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 15:15:04 UTC -1.7186 6.2886 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 14:45:03 UTC -1.7186 6.2886 300000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 14:15:03 UTC -1.7186 6.2886 250000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 13:45:03 UTC -1.8095 6.3795 250000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 13:15:04 UTC -1.8095 6.3795 250000
    F-STAR THERAPEUTICS INC FSTX 2023-03-08 12:45:04 UTC -1.8095 6.3795 85000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund FSTX -2800.0 shares, $-17696.0 2022-12-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments